Homepage > Company > Media > Pharma News > 2018 > Spain's Almirall to buy U.S. dermatology portfolio from Allergan

Spain's Almirall to buy U.S. dermatology portfolio from Allergan

Aug 3 (Reuters) - Spanish pharmaceutical company Almirall SA said on Friday it has agreed to buy a portfolio of five brands from U.S. firm Allergan for up to $650 million in cash.

Almirall said it would pay $550 million in cash upfront and that there is a possibility of an earn-out of up to $100 million based on business performance.

AUGUST 3б 2018

https://www.reuters.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)